Eosinophilic Fasciitis
Original Editor - Syeda Bushra Zehra Zaidi
Top Contributors - Syeda Bushra Zehra Zaidi and Vidya Acharya
Introduction
Eosinophilic Fasciitis (EF) is a rare and complex autoimmune disorder characterized by the inflammation and thickening of the fascia, the connective tissue that surrounds muscles, blood vessels, and nerves. The condition primarily affects the skin and soft tissues, often leading to significant physical limitations, pain, and discomfort. While the exact cause of EF is not fully understood, it is believed to result from an autoimmune reaction that leads to the abnormal accumulation of eosinophils (a type of white blood cell) in the fascia.[2]
This page provides an overview of eosinophilic fasciitis, including its symptoms, causes, diagnostic process, and treatment options.
Clinical Presentation and Symptoms
The symptoms of eosinophilic fasciitis can be highly variable, and the disease may develop gradually. Common symptoms of EF include:
- Swelling and Stiffness: The primary feature of EF is swelling in the affected areas, especially in the arms, legs, and torso. This swelling is often accompanied by skin thickening and tightness.
- Pain: Patients frequently experience pain and tenderness in the affected regions, which may worsen with movement.
- Skin Changes: The skin may appear shiny, thickened, or discolored. In some cases, the skin may have an "orange peel" appearance, indicative of the underlying fibrosis.
- Joint and Muscle Issues: EF can cause joint pain, stiffness, and muscle weakness, which can restrict mobility.
- Fatigue: Many individuals with EF report general fatigue or a feeling of being unwell.
As the disease progresses, the thickening of the fascia can lead to the permanent limitation of joint and muscle function.[3]
Causes and Risk Factors
The precise cause of eosinophilic fasciitis remains unknown. However, it is thought to arise from an abnormal immune response in which the body’s immune system attacks its own connective tissues. Potential contributing factors include:
- Infections: Certain viral or bacterial infections may trigger the onset of EF.
- Trauma or Surgery: Physical trauma or prior surgical procedures can sometimes act as a catalyst for the development of EF.
- Medications: Some medications, especially those that alter immune system function, have been associated with EF.
- Environmental Exposures: Exposure to toxins or chemicals may play a role in the onset of the disease.
- Genetics: Though not fully understood, there may be a genetic predisposition to EF.While these factors may contribute to the development of eosinophilic fasciitis, further research is necessary to establish definitive links between these variables and the disease.[4]
Diagnostic Approach
A multidisciplinary approach involving dermatologists, rheumatologists, and other specialists is often required for accurate diagnosis and management.[5][6]. Diagnosing eosinophilic fasciitis typically involves a combination of clinical evaluation, laboratory tests, and imaging studies. Due to its rarity and the overlap of symptoms with other disorders, EF can be difficult to diagnose. A comprehensive diagnostic approach may include:
Clinical Evaluation: A detailed medical history and physical examination are essential for identifying symptoms and ruling out other conditions.
Blood Tests: Blood tests often reveal elevated eosinophil levels (eosinophilia), as well as markers of systemic inflammation, such as elevated erythrocyte sedimentation rate (ESR) or C-reactive protein (CRP).[7]
Skin Biopsy: A biopsy of the affected skin or fascia can help confirm the diagnosis by revealing inflammation and an increase in eosinophil count.
Magnetic Resonance Imaging (MRI): MRI can provide a detailed assessment of fascia thickening and any associated muscle or tissue damage.
Electromyography (EMG): EMG tests may be used to assess muscle activity and exclude other possible causes of symptoms.
Management
While there is no cure for eosinophilic fasciitis, early intervention and appropriate treatment can help manage symptoms, reduce inflammation, and prevent long-term complications.
Medical Management
Treatment strategies typically focus on controlling the autoimmune response and alleviating the associated discomfort. Common treatment options include:
- Corticosteroids: Oral or intravenous corticosteroids (e.g., prednisone) are the mainstay of treatment, helping to reduce inflammation and control the immune system's overactivity.[8][9]
- Immunosuppressive Drugs: If corticosteroids are insufficient, immunosuppressive medications such as methotrexate or cyclophosphamide may be used to further modulate the immune response.[8]
- Biologic Therapies: In severe or refractory cases, biologic drugs, such as rituximab, may be considered to target specific immune pathways involved in the disease.[2]
- Supportive Care: Pain management, anti-inflammatory medications, and skin care (e.g., moisturizers to improve skin flexibility) may also be used to support overall well-being.[2]
Treatment plans are highly individualized, and ongoing monitoring is required to assess the effectiveness of therapies and adjust as needed.
Rehabilitation
Physical therapy is an integral part of treatment. Stretching and strengthening exercises can help maintain mobility, prevent muscle atrophy, and reduce the risk of contractures.[8]. A case study of a 21-year-old man with eosinophilic fasciitis (EF) showed remarkable improvement in pain levels, swelling, strength, joint ranges in all extremities and hand function, gait, and endurance after 2 months of inpatient rehabilitation. The rehabilitation program began 8 months after the onset of his symptoms and included splinting, application of physical modalities, massage, stretching and strengthening exercises and interdisciplinary pain management. [10]
Prognosis and Quality of Life
Eosinophilic fasciitis is a chronic condition that can have a significant impact on an individual's quality of life. However, with early diagnosis and appropriate management, many patients can achieve symptom control and maintain an active lifestyle. The course of the disease is highly variable, with some individuals experiencing spontaneous remission while others may have persistent or progressive symptoms.
Regular follow-up with healthcare providers is essential to monitor the condition, adjust treatments as necessary, and address any complications that may arise.[11]
Conclusion
Eosinophilic fasciitis is a rare and complex condition that can cause significant physical limitations and discomfort. A comprehensive, multidisciplinary approach to diagnosis and treatment is critical to managing the disease and improving outcomes for affected individuals. While the condition is chronic, early detection and personalized treatment plans can help manage symptoms and enhance the quality of life for those affected.
For more information or to schedule a consultation, please contact our medical team. We are committed to providing expert care and support for individuals living with eosinophilic fasciitis.
References
- ↑ Correa AL, Londoño Á, Ruiz AC, Mesa M. Eosinophilic fasciitis: a case report. Revista Colombiana de Reumatología (English Edition). 2018 Jan 1;25(1):63-8.
- ↑ 2.0 2.1 2.2 Lebeaux D, Sène D. Eosinophilic fasciitis (Shulman disease). Best Practice & Research Clinical Rheumatology. 2012 Aug 1;26(4):449-58.
- ↑ Ihn H. Eosinophilic fasciitis: from pathophysiology to treatment. Allergology International. 2019 Oct 1;68(4):437-9.
- ↑ Pinal-Fernandez I, Selva-O'Callaghan A, Grau JM. Diagnosis and classification of eosinophilic fasciitis. Autoimmunity reviews. 2014 Apr 1;13(4-5):379-82.
- ↑ Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. International journal of dermatology. 2008 Jan;47(1):29-35.
- ↑ Mazori DR, Femia AN, Vleugels RA. Eosinophilic fasciitis: an updated review on diagnosis and treatment. Current rheumatology reports. 2017 Dec;19:1-2.
- ↑ Nashel J, Steen V. The use of an elevated aldolase in diagnosing and managing eosinophilic fasciitis. Clinical rheumatology. 2015 Aug;34:1481-4.
- ↑ 8.0 8.1 8.2 Mazilu D, Boltașiu LA, Mardale DA, Bijă MS, Ismail S, Zanfir V, Negoi F, Balanescu AR. Eosinophilic fasciitis: current and remaining challenges. International Journal of Molecular Sciences. 2023 Jan 19;24(3):1982.
- ↑ Mendoza FA, Bai R, Kebede AG, Jimenez SA. Severe eosinophilic fasciitis: comparison of treatment with D-penicillamine plus corticosteroids vs. corticosteroids alone. Scandinavian journal of rheumatology. 2016 Mar 3;45(2):129-34.
- ↑ O'Laughlin TJ, Klima RR, Kenney DE. REHABILITATION OF EOSINOPHILIC FASCIITIS: A Case Reports. American journal of physical medicine & rehabilitation. 1994 Jul 1;73(4):286-92.
- ↑ Mango RL, Bugdayli K, Crowson CS, Drage LA, Wetter DA, Lehman JS, Peters MS, Davis MD, Chowdhary VR. Baseline characteristics and long‐term outcomes of eosinophilic fasciitis in 89 patients seen at a single center over 20 years. International Journal of Rheumatic Diseases. 2020 Feb;23(2):233-9.